Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial is studying how well giving dinaciclib works in treating patients with
 relapsed or refractory multiple myeloma. Dinaciclib may stop the growth of cancer cells by
 clocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES:

 I. To evaluate the efficacy (overall response rate) of single agent SCH 727965 in patients
 with relapsed or refractory multiple myeloma.

 SECONDARY OBJECTIVES:

 I. To evaluate the toxicities associated with use of single agent SCH 727965 in patients with
 relapsed or refractory multiple myeloma.

 II. To evaluate the response duration and progression free survival among patients with
 relapsed or refractory multiple myeloma undergoing treatment with single agent SCH 727965.

 III. To study the effect of SCH 727965 on myeloma cell proliferation, apoptotic rates and to
 assess the ability of the drug to inhibit drug targets (cyclin dependent kinases, cdk in the
 myeloma cell.

 OUTLINE: This is a multicenter, dose-escalation study.

 Patients receive dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the
 absence of disease progression or unacceptable toxicity.

 Blood and bone marrow samples are collected periodically for correlative studies. (US sites
 only)

 After completion of study treatment, patients are followed up for up to 3 years.
Inclusion Criteria:

 -  Relapsed or refractory multiple myeloma

 -  Measurable disease as defined by at least ONE of the following:

 -  Serum monoclonal protein >= 1.0 g/dL

 -  > 200 mg of monoclonal protein in the urine on 24 hour electrophoresis

 -  Serum immunoglobulin free light chain >= 10 mg/dL AND abnormal serum
 immunoglobulin kappa to lambda free light chain ratio

 -  ≤ 5 prior therapies; stem cell transplantation and preceding induction therapy will be
 considered as one therapy; NOTE: Patients must not be candidates for stem cell
 transplantation or should have had stem cells collected previously

 -  Life expectancy of ≥ 3 months

 -  ECOG performance status of 0, 1 or 2

 -  Absolute neutrophil count >= 1,000/mcL

 -  Platelets >= 75,000/mcL

 -  Hemoglobin >= 8 g/dL

 -  Total serum bilirubin within normal institutional limits

 -  AST (SGOT)/ALT(SGPT) =< 2.5 X institutional ULN

 -  Creatinine < 2.5 mg/dL

 -  Negative serum pregnancy test done ≤7 days prior to registration (for women of
 childbearing potential only); NOTE: Should a woman become pregnant or suspect she is
 pregnant while participating in this study, she should inform her treating physician
 immediately

 -  Ability to understand and the willingness to sign a written informed consent document

 -  Willingness to provide blood and bone marrow samples for mandatory research component
 of this study; (US sites only)

 Exclusion Criteria:

 -  Any of the following prior therapies:

 -  Myelosuppressive therapy for myeloma ≤ 3 weeks prior to registration or those who
 have not recovered from acute reversible adverse events due to agents
 administered > 3 weeks earlier

 -  Non-myelosuppressive agents like thalidomide or high dose corticosteroids ≤ 2
 weeks prior to registration

 -  Receiving any other investigational agents

 -  Concomitant high dose corticosteroids

 -  NOTE: Concurrent use of corticosteroids, but patients may be on chronic steroids
 (maximum dose 20 mg/day prednisone equivalent) if they are being given for
 disorders other than amyloid, i.e., adrenal insufficiency, rheumatoid arthritis,
 etc.

 -  NOTE: Bisphosphonates are considered to be supportive care rather than therapy,
 and are thus allowed while on protocol treatment

 -  Active malignancy with the exception of non melanoma skin cancer or in situ cervical
 or breast cancer

 -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
 infections or psychiatric illness/social situations that would limit compliance with
 study requirements

 -  Pregnant or nursing women; NOTE: Because there is an unknown but potential risk for
 adverse events in nursing infants secondary to treatment of the mother with SCH
 727965, breastfeeding should be discontinued if the mother is treated with SCH 727965

 -  Currently taking inhibitors/inducers of CYP3A4; (SCH 727965 metabolizes via the CYP3A4
 enzyme; there are potential drug interactions with concomitant use of CYP3A4 potent
 inhibitors/inducers; Principal Investigator should review each case and determine if
 patients on the CYP3A4 potent inhibitors/inducers are eligible and will make all
 effort to switch to alternative drugs; patients should not take grapefruit/ grapefruit
 juice or St. Johns' Wort)

 -  Men or women of childbearing potential who are unwilling to employ adequate
 contraception